PALB2 and breast carcinoma: A combination of breast cancer PRS in the top decile and a mutation in the CHEK2 variant increased the lifetime risk to 59% – a risk comparable to that seen in PALB2 mutation carriers – whereas those with a PRS in the bottom decile had a risk similar to the population level.